Clinical research studyHospital Length of Stay in Patients with Non-ST-segment Elevation Myocardial Infarction
Section snippets
Methods
The ACTION Registry-GWTG is a result of the merger between the American College of Cardiology Foundation's NCDR ACTION Registry and the American Heart Association's GWTG-Coronary Artery Disease Registry. The ACTION Registry-GWTG is a voluntary national quality improvement registry that began collecting data on January 1, 2007 on hospitalized ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction patients that are at least 18 years of age. This registry is
Baseline Characteristics
For the 39,107 patients with non-ST-segment elevation myocardial infarction in our analysis cohort, the median age overall was 64 (54, 75) years. Women made up 37.0% of the population, and 82.1% of patients were white. The median length of stay for the overall cohort in our study population was 3 (2, 5) days, and the distribution of length of stay is displayed in Figure 1. There were 13,047 (33.4%) patients with length of stay ≤2 days; 15,870 (40.6%) with length of stay 3-4 days; 6325 (16.1%)
Discussion
This study examined national patterns of hospital length of stay for over 39,000 non-ST-segment elevation myocardial infarction patients in the ACTION Registry-GWTG. In our analysis, we found that patients with longer length of stay were older, more likely to have comorbidities and in-hospital complications, and were at a higher calculated baseline risk of death. However, these patients were less often treated with evidence-based medications despite a lack of documented contraindications, and
Conclusions
This is one of the largest studies ever performed to examine the characteristics of patients admitted with non-ST-segment elevation myocardial infarction and their association with hospital length of stay. Patients with longer length of stay were older and had more comorbidities and in-hospital complications but were less likely to receive evidence-based medications and had delays in cardiac catheterization. Additionally, hospital admission on a Friday afternoon or evening and delays to cardiac
Acknowledgements
The authors would like to thank Erin LoFrese for her editorial contributions to this manuscript. Ms. LoFrese did not receive compensation for her contributions, apart from her employment at the institution where this study was conducted.
References (13)
- et al.
Length of hospital stay after acute myocardial infarction in the Myocardial Infarction Triage and Intervention (MITI) Project registry
J Am Coll Cardiol
(1996) - et al.
Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarctionPAMI-II Investigators. Primary Angioplasty in Myocardial Infarction
J Am Coll Cardiol
(1998) - et al.
Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score
Am Heart J
(2011) - et al.
Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Circulation
(2007) - et al.
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction
N Engl J Med
(2000) - et al.
A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion
N Engl J Med
(1988)
Cited by (0)
Funding: The ACTION Registry-GWTG is an initiative of the American College of Cardiology Foundation and the American Heart Association, with partnering support from the Society of Chest Pain Centers, Society of Hospital Medicine, and the American College of Emergency Physicians. The registry is sponsored by Bristol-Myers Squibb/Sanofi Pharmaceuticals. This project received infrastructure support from grant number U18HS010548 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.
Conflict of Interest: Dr Lopes reports research funding from Bristol Myers Squibb (<10K); Dr Newby reports research funding from Amylin, AstraZeneca, Bristol Myers Squibb, diaDexus, Eli Lilly & Co., Genetech, Glaxo Smith Kline, Merck & Co. Murdock, Regado Biosciences (>10K); and consulting from AstraZeneca, Regado Biosciences (<10K); Dr Wang reports research funding from Bristol Myers Squibb, Daiichi Sankyo, Heartscape Technologies, Lilly, Sanofi-Aventis, Schering-Plough Corporation, The Medicines Company (>10K); and personal royalties from Lilly (>10K); Dr Ho reports honoraria from Pfizer-Japan (<10K); and consulting from Wellpoint, Inc. (<10K); Dr Wiviott reports research funding from Eli Lilly, Daiichi Sankyo, Merck/Schering Plough (all >10K); and consulting from BMS/Sanfoi, AstraZeneca, Bayer, Medco (all <10K); Dr Peterson reports research funding from Bristol Myers Squibb, Eli Lilly & Co., Johnson & Johnson, Merck & Co., Sanofi-Aventis, American Heart Association, American College of Cardiology, and the Society of Thoracic Surgeons (>10K); Dr Roe reports research funding from Bristol Myers Squibb, Eli Lilly & Co., Novartis Pharmaceuticals, Schering-Plough Corporation (>10K); and consulting from Eli Lilly & Company, Glaxo Smith Kline, Novartis Pharmaceuticals, Orexigen (<10K); Bristol Myers Squibb, KAI Pharmaceuticals, and Sanofi-Aventis (>10K); Dr Granger reports research funding from Astellas Pharma US, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Glaxo Smith Kline, Medtronic Vascular, Merck & Co. (>10K); and consulting from AstraZeneca, Bristol Myers Squibb, Glaxo Smith Kline, Hoffman-LaRoche, Novartis Pharmaceuticals (<10K), and Boehringer Ingelheim (>10K). Dr Vavalle, Ms Chen, and Dr Shah have no disclosures to report.
Authorship: All authors had access to the data and a role in writing the manuscript.